Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 EUR | 0.00% |
|
0.00% | 0.00% |
28/06 | Ovoca Bio plc Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2021 | Ovoca Bio : Enrolls First Patient in Phase 2 Trial for Hypoactive Sexual Desire Disorder Treatment | MT |
Business Summary
At the end of 2022, the Group had a product in phase III clinical development (Orenetide).
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 88,458,806 | 42,053,448 ( 47.54 %) | 6,895,000 ( 7.795 %) | 47.54 % |
Company contact information
![address Ovoca Bio plc(OVXA)](https://cdn.zonebourse.com/static/address/1412402.png)
Group companies
Name | Category and Sector |
---|---|
Silver Star Ltd. (Bermuda)
|
Miscellaneous
|
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
0.00% | 9L | |
+15.20% | 12TCr | |
+19.67% | 11TCr | |
+18.95% | 2.6TCr | |
-23.86% | 1.94TCr | |
-19.03% | 1.59TCr | |
-20.90% | 1.51TCr | |
-46.14% | 1.51TCr | |
+63.85% | 1.49TCr | |
+4.49% | 1.39TCr |
- Stock Market
- Equities
- OVXA Stock
- Company Ovoca Bio plc